Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials

34Citations
Citations of this article
32Readers
Mendeley users who have this article in their library.

Abstract

Objectives Despite maximally tolerated statin therapy, many patients with high cardiovascular risk, with or without heterozygous familial hypercholesterolemia may require additional low-density lipoprotein cholesterol (LDL-C) reduction. We report pooled alirocumab (ALI) efficacy and safety data from eight Phase 3 trials in 4629 hypercholesterolemia patients, receiving background statin therapy. Material and methods Studies were pooled by ALI dose and control: ALI 75/150 mg every 2 weeks (Q2W; dose increased to 150 mg Q2W at Week 12 based on Week 8 LDL-C) versus ezetimibe (EZE; Pool 1) or placebo (PBO; Pool 2), and ALI 150 mg Q2W versus PBO (Pool 3). Results Mean baseline LDL-C was 109 vs. 105 mg/dL (Pool 1), 129 vs. 130 mg/dL (Pool 2) and 126 vs. 125 mg/dL (Pool 3). ALI 75/150 mg Q2W reduced LDL-C by 48.9% (vs. − 19.3% EZE) and 48.6% (vs. + 4.2% PBO) from baseline to Week 24, and ALI 150 mg Q2W reduced LDL-C by 60.4% (vs. + 0.5% PBO; all p < 0.0001). LDL-C reductions were sustained to Week 104. Risk-based LDL-C goals (< 70 mg/dL or < 100 mg/dL) were achieved by 78.0%, 75.2%, and 79.0% (Pool 1–3) of ALI-treated patients (vs. 52.4%, 6.4%, and 8.4%, respectively, for controls) at Week 24. Consistent reductions were observed in apolipoprotein B, non-high-density lipoprotein cholesterol, and lipoprotein (a) (p < 0.0001 vs. control). Common adverse events in ALI-treated patients were nasopharyngitis, injection-site reactions, upper respiratory tract infections, and influenza. Conclusions Alirocumab treatment significantly reduced LDL-C in high cardiovascular risk patients, enabling most to achieve risk-based LDL-C goals.

Cite

CITATION STYLE

APA

Farnier, M., Gaudet, D., Valcheva, V., Minini, P., Miller, K., & Cariou, B. (2016). Efficacy of alirocumab in high cardiovascular risk populations with or without heterozygous familial hypercholesterolemia: Pooled analysis of eight ODYSSEY Phase 3 clinical program trials. International Journal of Cardiology, 223, 750–757. https://doi.org/10.1016/j.ijcard.2016.08.273

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free